pabolizumab

DRUG2 trials

Sponsors

Fudan University, Peking University Cancer Hospital & Institute

Conditions

Gastric AdenocarcinomaGastric CancerNSCLC Patients

Unknown Phase

Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

Fudan UniversityNSCLC Patients

Start: 2020-06-08End: 2022-12-31Target: 200Updated: 2020-06-11

Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma

Peking University Cancer Hospital & InstituteGastric Adenocarcinoma, Gastric Cancer

Start: 2023-03-01End: 2024-03-01Target: 32Updated: 2023-04-18